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Abstract: While MIC distributions and percent susceptibility for cefepime and ceftazidime 
are generally similar among Pseudomonas aeruginosa, we noted an increasing discordance in 
susceptibility favoring ceftazidime at our hospital. Quantitative reverse transcriptase-polymerase 
chain reaction was utilized to explore overexpression of the MexXY-OprM efﬂ  ux as the 
mechanism for this phenotype proﬁ  le. Thirteen of 15 (87%) randomly selected isolates 
had mexY gene expression levels of 5.8–40.8-fold relative to the wild-type reference strain. While 
mexY overexpression was noted in the majority of isolates, other resistance mechanisms appear to 
contribute to the observed phenotypic proﬁ  le of the Pseudomonas aeruginosa studied. Clinicians 
must understand not only the magnitude of difference in the MIC proﬁ  les between agents, but also 
the mechanism(s) responsible for these observations if strategies (ie, pharmacodynamic dosing) 
are to be designed to optimize patient care outcomes in the face of increasing resistance.
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Introduction
Pseudomonas aeruginosa is a commonly occurring nosocomial Gram-negative 
pathogen that is often associated with antibiotic resistant phenotypes, a proﬁ  le that 
has been linked to therapeutic failure (Georges et al 2006; Mesaros et al 2007). This 
organism can confer multiple mechanisms of resistance, including β-lactamase pro-
duction, expression of efﬂ  ux pumps, and reduction of its outer-membrane (porin) 
permeability (Bonomo and Szabo 2006; Poole 2007; Tenover 2006). While resistance 
due to these mechanisms may be expressed concurrently, the presence of efﬂ  ux 
pumps are an important singular determinant of multi-drug resistance (Bonomo 
and Szabo 2006; Dubois et al 2001; Nikaido and Zgurskaya 1999; Tenover 2006a; 
Tenover 2006b). There exist in P. aeruginosa naturally occurring multidrug-efﬂ  ux 
(Mex) pumps that consist of three components: 1) a cytoplasmic-membrane associ-
ated the resistance-nodulation-division (RND) transmembrane protein transporter 
(eg, MexB, MexY), 2) an outer membrane gated channel (eg, OprM, OprN, OprJ), 
and 3) a periplasmic membrane fusion lipoprotein or pump assembly (eg, MexA, 
MexX) linking the two membrane bound components (Jeannot et al 2005). Four 
predominant Mex efﬂ  ux systems have been reported: MexAB-OprM, MexCD-OprJ, 
MexEF-OprN, and MexXY-OprM (Aeschlimann 2003; Nikaido and Zgurskaya 1999; 
Schweizer 2003; Tenover 2006); each has a preferential set of antimicrobial agent 
substrates. For instance, MexXY-OprM is capable of extruding cefepime, cefotaxime, 
levoﬂ  oxacin, ciproﬂ  oxacin, amikacin, gentamicin, tobramycin, erythromycin, tetracy-
cline, and meropenem (Aeschlimann 2003; Masuda et al 2000; Pournaras et al 2005). 
The overexpression of MexXY in P. aeruginosa isolates was initially reported by International Journal of Nanomedicine 2008:1 52
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Westbrock-Wadman and colleagues (1999) and then by 
Wolter and colleagues (2004) as the mechanism respon-
sible for ﬂ  uoroquinolone and aminoglycosides resistance, 
respectively.
Cefepime and ceftazidime are two cephalosporins 
used clinically against P. aeruginosa. Minimum inhibitory 
concentrations (MICs) and percent susceptibility for these 
agents are generally similar (Flamm et al 2004; Karlowsky 
et al 2005); however, in 2006, Hocquet et al reported the 
overexpression of the MexXY-OprM efﬂ  ux pump as a major 
mechanism for P. aeruginosa isolates that were cefepime 
resistant/ceftazidime susceptible in two French hospitals 
(Hocquet et al 2006). The MIC50 for cefepime was 2-fold 
higher than ceftazidime in this phenotype. While cefepime is a 
substrate for MexXY-OprM, ceftazidime does not appear to be 
affected by this type of efﬂ  ux pump (Aeschlimann 2003).
At our 810 bed inner city teaching hospital, cefepime is 
widely used for empiric and deﬁ  nitive therapy of P. aeruginosa. 
After the formulary replacement of ceftazidime with cefepime 
in 2000, P. aeruginosa susceptibility to cefepime appeared 
to decline while the percent susceptible to ceftazidime 
remained stable over the next several years. Initially, we 
attributed this to errors in automated testing systems since 
it had been previously reported that some systems over 
report resistance for cefepime (Biedenbach et al 1999; Jones 
et al 1998; Sader et al 2006). Recently, however, we have 
detected P. aeruginosa strains that appear to be resistant to 
all β-lactams except ceftazidime. Upon further evaluation, 
these recent isolates were susceptible or intermediate to 
ceftazidime, non-susceptible to cefepime, and had cefepime 
MICs that were at least 2-fold greater than ceftazidime. As 
a result of these observations we sought to determine if one 
potential explanation for this phenotype proﬁ  le was the 
overexpression of the MexXY-OprM efﬂ  ux pump.
Materials and methods
P. aeruginosa clinical isolates collected at Hartford Hospital 
during an institutional survey in 2005–2006 were selected for 
analysis. We randomly chose 15 nonduplicate P. aeruginosa 
that were susceptible or intermediate to ceftazidime, non-
susceptible to cefepime, and had cefepime MICs that were 
at least 2-fold greater than that of ceftazidime. Most clinical 
isolates (n = 9) were from respiratory specimens; 6 of the 9 were 
obtained from patients diagnosed with ventilator-associated 
pneumonia. The remaining isolates were collected from the 
urinary tract and wound samples. Cefepime and ceftazidime 
MICs were determined by E-Test® (AB Biodisk, Solna, 
Sweden) in duplicate and the mean values are reported.
Pulsed-ﬁ  eld gel electrophoresis
Clonality was assessed by means of pulsed-field gel 
electrophoresis (PFGE). Chromosomal DNA was prepared 
by the method of Matushek et al (Matushek et al 1996), 
digested with XbaI, and separated by electrophoresis on a 
CHEF Mapper apparatus (BioRad Laboratories, Richmond, 
CA) at a voltage of 6 V/cm at 14 °C for 21 h, with pulse 
times linearly ramped from 1 to 25s. Strain relatedness 
was determined according to the criteria by Tenover et al 
(Tenover et al 1995).
Isolation of total RNA
Strains were inoculated in 2 ml calcium-adjusted Mueller 
Hinton broth (CaMHB) and grown overnight at 35 °C. Strains 
were diluted 1:1000 in CaMHB and cultures grown to an 
absorbance at 600 nm of 0.3 (corresponding to logarithmic 
phase). A 1.8 ml aliquot of this culture was added to 3.6 ml 
of RNA easy bacteria protect solution (Qiagen, Valencia, 
CA) and total RNA was isolated using the Qiagen RNeasy 
kit (Qiagen). Residual DNA was eliminated by an on-
column DNAse digestion using the RNAse-free DNase 
set (Qiagen), and the RNA was resuspended in 30 μl of 
RNAse-free H2O.
Synthesis of cDNA for reverse 
transcriptase-polymerase chain
reaction (RT-PCR)
Reverse transcription to cDNA was performed using the 
Transcriptor First Strand cDNA Synthesis Kit (Roche, 
Indianapolis, IN) with random hexamers (60 μM) as 
described in depth by the manufacturer’s instructions. 
The initial reaction mixture contained 2 μg of total RNA, 
which was subsequently divided into two aliquots. Reverse 
transcriptase was added to one aliquot, while the other aliquot 
served as a negative control to detect any residual genomic 
DNA in the RNA preparation. The cDNAs were stored 
at −20 °C until further analyses.
RT-PCR analysis
Expression of the MexXY-OprM operon was assessed by 
quantitative RT-PCR with speciﬁ  c primers to determine the 
transcript levels of the gene mexY (Hocquet et al 2006) as 
previously described. A LightCycler® 2.0 RT-PCR machine 
(Roche, software version 3.5) was used for the quantiﬁ  cation 
of cDNA. Duplicate PCR reactions were performed using 
the LightCycler® FastStart DNA Master PLUS SYBR Green I 
kit (Roche) according to manufacturer’s instructions. A ﬁ  nal 
concentration of 10% DMSO and 100 ng cDNA was used International Journal of Nanomedicine 2008:1 53
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in a total volume of 20 μl for each reaction. After a 10 min 
activation of the Taq polymerase at 95 °C, 40 cycles of 15s 
at 95 °C, 5s at 62 °C, 12s at 72 °C were performed. A melt 
curve was run at the end of 40 cycles to test for the presence 
of a unique PCR reaction product.
The isogenic strains PAO1 (PAM1020, wild-type 
efﬂ  ux expression) (Lomovskaya et al 1999) and PAM1323 
(MexXY-OprM overexpressed) (gifts from O. Lomovskaya, 
Mpex Pharmaceuticals) served as controls and were analyzed 
in parallel with the clinical strains. The housekeeping gene, 
rpoD (sigma factor of RNA polymerase) (Savli et al 2003), 
served as the internal standard to correct for variations in 
the amount of starting template material. The threshold 
cycle (Ct) of each sample, which identiﬁ  ed the cycle number 
during PCR when ﬂ  uorescence exceeded a threshold value, 
was determined by the software, and the relative expression 
of mexY was assessed using the ΔΔCt method, as described 
previously (Livak and Schmittgen 2001). The results 
represent relative expression levels (fold change) for a given 
target gene in the tested isolates compared to the PAO1 
wild-type strain. Additionally, three clinical strains, having 
the same/similar MICs to both cefepime and ceftazidime, 
were used as efﬂ  ux controls and showed mRNA transcript 
levels of mexY very close to that of PAO1 (0.8 times). 
The gain-of-efﬂ  ux control strain demonstrated increased 
expression of mexY (26.2 times). A speciﬁ  c mRNA level of 
mexY greater than 4 times that of the wild-type susceptible 
strain PAO1 was considered to be a MexXY overproducer.
Results
After the introduction and exclusive use of cefepime in 2000, 
our P. aeruginosa susceptibility as noted by the institutional 
antibiogram has been relatively constant for ceftazidime but 
appeared to drop for cefepime (Table 1).
The cefepime/ceftazidime MIC ratio of the studied 
isolates ranged from 2.7 to  32 (Table 2). As determined by 
PFGE, ten of the ﬁ  fteen isolates clustered into three clonal 
groups. Group 1 consisted of the closely related isolates, 
PSA766 and 987 (2-band difference); Group 2 consisted 
of the indistinguishable PSA828, 882, and 782, and the 
closely-related PSA805 (2-band difference), and Group 3 
consisted of the indistinguishable PSA814, 859, and 808, 
and the closely-related PSA855 (2-band difference). The 
ﬁ  ve remaining isolates were unique pulsotypes.
In contrast to the dually susceptible control isolates, which 
showed no appreciable increase in mexY transcript levels, thirteen 
of the 15 isolates (87%) exhibited a marked increased in mexY 
gene expression levels (from 5.8- to 40.8-fold) relative to the 
reference wild-type susceptible strain PAO1 (Table 2). The two 
clinical isolates that did not appear to show overexpression are 
designated as PSA784 and PSA831. While mexY overexpression 
was noted in the majority of these isolates, this was poorly 
correlated to the cefepime/ceftazidime MIC ratio. For example, 
while isolates PSA859 and PSA808 expressed high levels of 
mexY (21.3- and 34.3-fold higher than those observed in PAO1), 
their MIC ratios were 2.7 and 4.0, respectively. Moreover while 
PSA808 and PSA831 had the same cefepime/ceftazidime MIC 
ratio, PSA808 demonstrated high mexY expression (31.8-fold 
more than PAO1), while PSA831 did not.
Additionally, many of the MexY positive strains were 
multi-drug resistant. All 13 of these strains were resistant 
to ciproﬂ  oxacin and levoﬂ  oxacin with the majority of MICs 
 32 μg/ml. Forty-six percent (6/13) were meropenem 
nonsusceptible (1 intermediate, 5 resistant) and 1/13 (8%) 
was piperacillin-tazobactam resistant (MIC   256 μg/ml). 
Aminoglycoside MIC data were available for only 9 isolates, 
8 of which were MexY positive: 5/8 were gentamicin 
resistant, 3/8 were resistant to tobramycin.
Table 1 Hartford Hospital susceptibility for Pseudomonas aeruginosa to cefepime and ceftazidime from the year of cefepime formulary 
introduction to present
Year Collected # isolates* Susceptibility (%) Difference (%)
Cefepime Ceftazidime
2000 945 77 81 4
2001 1041 74 87 13
2002 1022 75 85 10
2003 900 74 82 8
2004 1207 72 81 9
2005 1400 65 77 12
2006 1256 69 82 13
Note: *Isolates collected hospital-wide.International Journal of Nanomedicine 2008:1 54
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Table 2 Results of MICs, PFGE, relative expression of mexY in Pseudomonas aeruginosa expressing the cefepime resistant/ceftazidime 
nonresistant phenotype
Strain ID PFGEa MIC (μg/ml) FEP/CAZ MIC ratio Speciﬁ  c mRNA levelb mexY Overexpressionc
FEP CAZ
Wild-type efﬂ  ux strain PAO1 − 1.5 1.25 1.20 1.0
Susceptible clinical strains (n = 3) − 1.5–3 1.5–3 1.0 –1.5 0.8
Gain-of-efﬂ  ux strain PAM 1323 − 7 1.25 5.60 26.2 +
PSA 766 NPSA1 24 8 3.00 5.8 +
PSA 987 NPSA1a 32 8 4.00 5.9 +
PSA 828 NPSA2 16 3 5.33 11.2 +
PSA 882 NPSA2 32 6 5.33 7.0 +
PSA 782 NPSA2 24 4 6.00 11.8 +
PSA 805 NPSA2a 24 6 4.00 6.8 +
PSA 814 NPSA3 128 12 10.67 40.8 +
PSA 859 NPSA3 32 8 4.00 21.3 +
PSA 808 NPSA3 16 6 2.67 31.8 +
PSA 855 NPSA3a 24 6 4.00 22.8 +
PSA 820 NPSA4 12 2 6.00 18.1 +
PSA 932d NPSA5 512 16  32.00 16.7 +
PSA 776 NPSA6 16 4 4.00 34.3 +
PSA 784 NPSA7 32 6 5.33 2.6 −
PSA 831 NPSA8 16 6 2.67 0.7 −
Abbreviations: CAZ, ceftazidime; FEP, cefepime; MIC, minimum inhibitory concentration; PFGE, pulsed-ﬁ  eld gel electrophoresis.
Notes: aIsolates with clonal relations were grouped and separated by thinner line; bSpeciﬁ  c mRNAs were quantiﬁ  ed by real-time PCR after retrotranscription. Values are means 
of two independent determinations and are expressed relative to PAO1, which was set at 1.0;  cmexY overexpression is indicated by a + sign;  dExperimentally determined cefepime 
MIC   256 μg/ml; for calculation purposes, the value of 512 was utilized.
Together these data suggest that while the overexpression 
of the MexXY-OprM efﬂ  ux pump may play an important 
role in our noted cefepime and ceftazidime MIC discordance, 
other currently unidentiﬁ  ed mechanisms appear are contribute 
this phenotype proﬁ  le.
Discussion
To our knowledge, these are the ﬁ  rst US derived data set to 
suggest that the MexXY-OprM efﬂ  ux pump is a contributory 
factor for the observed discordant susceptibility proﬁ  le 
between cefepime and ceftazidime in P. aeruginosa. Our 
results also conﬁ  rm that the discordant MICs observed 
between cefepime and ceftazidime are not simply attributable 
to errors in the automated susceptibility systems but in fact, 
occur at least in part from mexY gene overexpression.
The majority of the P. aeruginosa isolates analyzed in 
this study over expressed the MexXY-OprM efﬂ  ux pump. 
The degree of mexY gene overexpression and variability was 
similar between our study (5.8–40.8-fold) and that of Hocquet 
and colleagues (2006) (4.0–39.0-fold). Some of our clinical 
isolates also displayed resistance to meropenem, ciproﬂ  oxacin, 
levoﬂ  oxacin, gentamicin and tobramycin, all of which are 
known to be MexXY-OprM substrates (Aeschlimann 2003; 
Masuda et al 2000; Pournaras et al 2005).
The poor correlation between the cefepime/ceftazidime 
MIC ratio and the overexpression of mexY may be 
explained by the presence of other resistance mechanisms 
(ie, β-lactamases, outer-membrane proteins and/or other 
types of efflux. While studies to fully elucidate other 
possible mechanisms were not undertaken, the production 
of a β-lactamase, OXA-31, has been reported to also result 
in a cefepime resistant/ceftazidime susceptible phenotype 
in P. aeruginosa (Aubert et al 2001). Double efﬂ  ux pumps 
(MexAB-OprM and MexXY-OprM) have also been 
identiﬁ  ed in some strains of P. aeruginosa that were resistant 
to meropenem and cefepime but susceptible to ceftazidime 
(Pournaras et al 2005).
Currently, the true prevalence of MexXY-OprM 
expressing P. aeruginosa is unknown at our hospital, so 
these data, along with declining cefepime susceptibilities 
have prompted us to empirically use higher cefepime 
dosages based on pharmacodynamics (eg, 2 g every International Journal of Nanomedicine 2008:1 55
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8 hours as prolonged infusions) or choose alternative 
antibiotics (ie, piperacillin/tazobactam). Additionally, the 
use of ceftazidime as deﬁ  nitive therapy for ceftazidime 
susceptible/cefepime non-susceptible P. aeruginosa has 
been considered.
In conclusion, our observation of MIC discordance 
between cefepime and ceftazidime in P. aeruginosa appears 
in part to be due to the overexpression of the MexXY-OprM 
efﬂ  ux pump. Additional studies are required to fully elucidate 
the mechanism(s) responsible for this atypical phenotypic 
proﬁ  le in P. aeruginosa.
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